Filing Flows › Strive (ASST) › Q2 2026 › vs Q1 2026
Strive (ASST) Q2 2026 vs Q1 2026 (quarter over quarter)
Strive's revenue rose $181K (+7%) from $2.8M in Q1 2026 to $2.9M in Q2 2026. The biggest changes: Investment advisory fees +$165K (+12%); Medical device revenues +$18K (+1%); Other revenue −$2K (-5%).
Strive, Q2 2026: revenue $2.9M (+95% year over year), net loss $258M, operating cash flow −$8.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Investment advisory fees | $1.5M | $1.3M | $165K | +12% |
| Medical device revenues | $1.4M | $1.4M | $18K | +1% |
| Other revenue | $41K | $43K | −$2K | -5% |
| Revenue | $2.9M | $2.8M | $181K | +7% |
| Other income, net | $646K | $47.2M | −$46.6M | -99% |
| Net loss | $258M | $266M | −$8.3M | -3% |
| Costs & expenses | $261M | $316M | −$54.7M | -17% |
| Operating costs | $261M | $316M | −$54.7M | -17% |
| Sales & marketing | $79K | $116K | −$37K | -32% |
| General & admin | $6.4M | $5.9M | $490K | +8% |
| Other operating costs | $255M | $310M | −$55.2M | -18% |
| Operating cash sources | $258M | $266M | −$8.3M | -3% |
| Depreciation & amortization | $86K | $90K | −$4K | -4% |
| Share-based compensation | $5.7M | $6.5M | −$845K | -13% |
| Working capital & other | $243M | $228M | $15.1M | +7% |
| Cash used in operations | $8.4M | $31.0M | −$22.6M | -73% |
| Net loss absorbed | $258M | $266M | −$8.3M | -3% |
Questions
How much did Strive's revenue grow quarter over quarter in Q2 2026?
Strive's revenue rose $181K (+7%) from $2.8M in Q1 2026 to $2.9M in Q2 2026.
What drove Strive's revenue change in Q2 2026?
Investment advisory fees +$165K (+12%); Medical device revenues +$18K (+1%); Other revenue −$2K (-5%).